Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1270282
Max Phase: Preclinical
Molecular Formula: C24H24N2O2
Molecular Weight: 372.47
Molecule Type: Small molecule
Associated Items:
ID: ALA1270282
Max Phase: Preclinical
Molecular Formula: C24H24N2O2
Molecular Weight: 372.47
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN1CC[C@]23Cc4nc5ccccc5cc4C[C@@]2(O)[C@H]1Cc1ccc(O)cc13
Standard InChI: InChI=1S/C24H24N2O2/c1-26-9-8-23-14-21-17(10-16-4-2-3-5-20(16)25-21)13-24(23,28)22(26)11-15-6-7-18(27)12-19(15)23/h2-7,10,12,22,27-28H,8-9,11,13-14H2,1H3/t22-,23-,24-/m1/s1
Standard InChI Key: NFXFNBIPWUYEIM-WXFUMESZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 372.47 | Molecular Weight (Monoisotopic): 372.1838 | AlogP: 2.97 | #Rotatable Bonds: 0 |
Polar Surface Area: 56.59 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 10.20 | CX Basic pKa: 8.05 | CX LogP: 3.21 | CX LogD: 2.47 |
Aromatic Rings: 3 | Heavy Atoms: 28 | QED Weighted: 0.64 | Np Likeness Score: 0.89 |
1. Nagase H, Nemoto T, Matsubara A, Saito M, Yamamoto N, Osa Y, Hirayama S, Nakajima M, Nakao K, Mochizuki H, Fujii H.. (2010) Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration., 20 (21): [PMID:20850307] [10.1016/j.bmcl.2010.08.083] |
2. Ida Y, Matsubara A, Nemoto T, Saito M, Hirayama S, Fujii H, Nagase H.. (2012) Synthesis of quinolinomorphinan derivatives as highly selective δ opioid receptor ligands., 20 (19): [PMID:22967810] [10.1016/j.bmc.2012.08.004] |
3. Kutsumura N, Koyama Y, Nagumo Y, Nakajima R, Miyata Y, Yamamoto N, Saitoh T, Yoshida N, Iwata S, Nagase H.. (2017) Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives., 25 (16): [PMID:28662966] [10.1016/j.bmc.2017.06.026] |
4. Fujii H, Uchida Y, Shibasaki M, Nishida M, Yoshioka T, Kobayashi R, Honjo A, Itoh K, Yamada D, Hirayama S, Saitoh A.. (2020) Discovery of δ opioid receptor full agonists lacking a basic nitrogen atom and their antidepressant-like effects., 30 (12): [PMID:32299730] [10.1016/j.bmcl.2020.127176] |
5. Iio K, Kutsumura N, Nagumo Y, Saitoh T, Tokuda A, Hashimoto K, Yamamoto N, Kise R, Inoue A, Mizoguchi H, Nagase H.. (2022) Synthesis of unnatural morphinan compounds to induce itch-like behaviors in mice: Towards the development of MRGPRX2 selective ligands., 56 [PMID:34861349] [10.1016/j.bmcl.2021.128485] |
Source(1):